Alerts will be sent to your verified email
Verify Email
MARKSANS
|
Marksans Pharma
|
Procter&Gamble Healt
|
FDC
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
25.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
13.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
1.7 % | n/a | 2.06 % |
|
Financials
|
|||
|
5 yr Average ROE
|
18.16 % | 30.46 % | 13.66 % |
|
5yr average Equity Multiplier
|
1.35 | 2.99 | 1.57 |
|
5yr Average Asset Turnover Ratio
|
0.99 | 0.57 | 0.54 |
|
5yr Avg Net Profit Margin
|
13.73 % | 17.93 % | 16.24 % |
|
Price to Book
|
4.36 | 13.93 | 2.99 |
|
P/E
|
26.99 | 35.93 | 24.96 |
|
5yr Avg Cash Conversion Cycle
|
69.54 Days | -158.56 Days | -14.0 Days |
|
Inventory Days
|
87.55 Days | 36.98 Days | 59.23 Days |
|
Days Receivable
|
69.35 Days | 29.14 Days | 21.91 Days |
|
Days Payable
|
84.4 Days | 177.2 Days | 86.54 Days |
|
5yr Average Interest Coverage Ratio
|
32.98 | 337.3 | 93.3 |
|
5yr Avg ROCE
|
23.15 % | 19.93 % | 14.95 % |
|
5yr Avg Operating Profit Margin
|
19.67 % | 24.91 % | 18.97 % |
|
5 yr average Debt to Equity
|
0.02 | 0.0 | 0.0 |
|
5yr CAGR Net Profit
|
21.8 % | -4.58 % | 4.94 % |
|
5yr Average Return on Assets
|
13.43 % | 10.24 % | 8.73 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
43.87 % | 51.82 % | 69.66 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-4.38 % | 0.0 | 0.3 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.91 % | 4.1 % | 0.49 % |
|
Marksans Pharma
|
Procter&Gamble Healt
|
FDC
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|